Aurora Kinase
Aurora Kinase(极光激酶)
Aurora kinases are a family of serine-threonine kinases of three highly homologous members, including aurora A kinase, aurora B kinase and aurora C kinase, which are responsible for chromosome assembly and segregation during mitosis. Aurora kinases are characterized by two domains: a regulatory domain in the NH2 terminus and a catalytic domain in the COOH terminus, in which an A-Box and a D-Box found correspondingly in each domain are responsible for protein degradation. Aurora A kinase plays an important role in centrosome function and duplication, mitotic entry and bipolar spindle assembly; while Aurora B kinase is the catalytic component of the chromosomal passenger complex regulating the accurate segregation of the chromatids at mitosis, histone modification and cytokinesis. Aurora C kinase is less studied and expressed restrictedly in the testes.
Aurora Kinase 相关产品(62)
- GC11549VX-680 (MK-0457,Tozasertib)CAS: 639089-54-6纯度: >99.50%
VX-680 (MK-0457,Tozasertib)是一种有效的Aurora激酶抑制剂，对Aurora A/B/C的K i 值分别为0.6、18、4.6nM，具有抗癌活性。
- GC12690MLN8237 (Alisertib)CAS: 1028486-01-2纯度: >99.00%
Alisertib (MLN8237) 作为一种在研、可口服的选择性极光 A 激酶抑制剂，通常用于治疗实体瘤和血液系统恶性肿瘤。
- GC12145ENMD-2076 L-(+)-Tartaric acidCAS: 1291074-87-7纯度: >98.50%
ENMD-2076 L-(+)-Tartaric acid 是一种多靶点激酶抑制剂，对 Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1 的 IC50 为 1.86、14、58.2、15.9、92.7、70.8、56.4 nM , FGFR2, Src, PDGFRα, 分别。
- GC13332Aurora A Inhibitor ICAS: 1158838-45-9纯度: >99.00%
A potent and selective inhibitor of Aurora A kinase
- GC16378TC-A 2317 hydrochlorideCAS: 1245907-03-2
TC-A 2317 hydrochloride 是一种具有口服活性的 Aurora A 激酶抑制剂 (Ki=1.2 nM)。 TC-A 2317 hydrochloride 对 Aurora B 激酶 (Ki=101 nM) 和其他 60 种激酶具有出色的选择性、良好的细胞渗透性和良好的 PK 曲线。抗肿瘤活性。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC10442 | MK-8745 | 885325-71-3 | >99.00% | |
An Aurora A kinase inhibitor | ||||
| GC11549 | VX-680 (MK-0457,Tozasertib) | 639089-54-6 | >99.50% | |
VX-680 (MK-0457,Tozasertib)是一种有效的Aurora激酶抑制剂，对Aurora A/B/C的K i 值分别为0.6、18、4.6nM，具有抗癌活性。 | ||||
| GC12690 | MLN8237 (Alisertib) | 1028486-01-2 | >99.00% | |
Alisertib (MLN8237) 作为一种在研、可口服的选择性极光 A 激酶抑制剂，通常用于治疗实体瘤和血液系统恶性肿瘤。 | ||||
| GC14409 | ZM 447439 | 331771-20-1 | >98.00% | |
Selective inhibitor of Aurora B kinase | ||||
| GC14651 | Reversine | 656820-32-5 | >98.00% | |
Reversine是一种靶向Aurora A激酶、Aurora B激酶和MPS1（Monopolar Spindle 1）激酶的非特异性、具有口服活性的小分子抑制剂。Reversine常用于细胞分化和多种癌症的研究。 | ||||
| GC14709 | AZD1152 | 722543-31-9 | >99.50% | |
AZD1152是一种高度选择性的Aurora B激酶（AURKB）抑制剂，IC 50 值为0.37nM。AZD1152是一种前体药物，在体内转化为活性形式AZD1152-hydroxyquinazoline pyrazol anilide（AZD1152-hQPA），主要用于研究与治疗急性髓系白血病等恶性肿瘤。 | ||||
| GC14955 | Barasertib (AZD1152-HQPA) | 722544-51-6 | >99.00% | |
A selective Aurora kinase B inhibitor | ||||
| GC10008 | GSK1070916 | 942918-07-2 | >98.50% | |
A potent inhibitor of Aurora B and C kinases | ||||
| GC11085 | TAK-901 | 934541-31-8 | >98.00% | |
A non-selective inhibitor of Aurora kinases | ||||
| GC12145 | ENMD-2076 L-(+)-Tartaric acid | 1291074-87-7 | >98.50% | |
ENMD-2076 L-(+)-Tartaric acid 是一种多靶点激酶抑制剂，对 Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1 的 IC50 为 1.86、14、58.2、15.9、92.7、70.8、56.4 nM , FGFR2, Src, PDGFRα, 分别。 | ||||
| GC13102 | XL228 | 898280-07-4 | >99.00% | |
A tyrosine kinase inhibitor | ||||
| GC13198 | AMG-900 | 945595-80-2 | >98.00% | |
A selective pan-Aurora kinase inhibitor | ||||
| GC13332 | Aurora A Inhibitor I | 1158838-45-9 | >99.00% | |
A potent and selective inhibitor of Aurora A kinase | ||||
| GC13668 | Phthalazinone pyrazole | 880487-62-7 | - | |
Potent, selective inhibitor of Aurora kinase A | ||||
| GC13837 | SNS-314 Mesylate | 1146618-41-8 | >99.50% | |
A pan-Aurora kinase inhibitor | ||||
| GC14566 | CCT137690 | 1095382-05-0 | >99.00% | |
An inhibitor of Aurora kinases and FLT3 | ||||
| GC14592 | KW 2449 | 1000669-72-6 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC15106 | CYC116 | 693228-63-6 | >98.00% | |
A potent Aurora kinase inhibitor | ||||
| GC15711 | Aurora Kinase Inhibitor III | 879127-16-9 | >99.00% | |
A potent inhibitor of Aurora A kinase | ||||
| GC16378 | TC-A 2317 hydrochloride | 1245907-03-2 | - | |
TC-A 2317 hydrochloride 是一种具有口服活性的 Aurora A 激酶抑制剂 (Ki=1.2 nM)。 TC-A 2317 hydrochloride 对 Aurora B 激酶 (Ki=101 nM) 和其他 60 种激酶具有出色的选择性、良好的细胞渗透性和良好的 PK 曲线。抗肿瘤活性。 | ||||
| GC16519 | ENMD-2076 | 934353-76-1 | >98.00% | |
A multi-kinase inhibitor | ||||
| GC16614 | SCH-1473759 | 1094069-99-4 | - | |
SCH-1473759 是一种极光抑制剂，对极光 A 和 B 的 IC50 分别为 4 和 13 nM。 | ||||
| GC17196 | Hesperadin | 422513-13-1 | >98.00% | |
Hesperadin是一种竞争性ATP结合抑制剂，对Aurora B激酶的IC 50 为250nM。 | ||||
| GC17455 | TAK-632 | 1228591-30-7 | >98.00% | |
A selective pan-Raf inhibitor | ||||